Swiss National Bank Sells 122,100 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Swiss National Bank cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 3.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,501,700 shares of the company's stock after selling 122,100 shares during the period. Swiss National Bank owned 0.31% of Teva Pharmaceutical Industries worth $36,558,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in TEVA. Commonwealth Equity Services LLC lifted its stake in shares of Teva Pharmaceutical Industries by 5.2% in the third quarter. Commonwealth Equity Services LLC now owns 255,477 shares of the company's stock valued at $2,606,000 after buying an additional 12,587 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Teva Pharmaceutical Industries by 1.1% in the third quarter. Bank of New York Mellon Corp now owns 1,902,235 shares of the company's stock valued at $19,403,000 after purchasing an additional 19,906 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Teva Pharmaceutical Industries by 9.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 412,277 shares of the company's stock worth $4,205,000 after purchasing an additional 34,623 shares during the period. Strs Ohio lifted its position in Teva Pharmaceutical Industries by 84.1% in the third quarter. Strs Ohio now owns 617,938 shares of the company's stock worth $6,302,000 after purchasing an additional 282,300 shares during the period. Finally, IFM Investors Pty Ltd increased its holdings in Teva Pharmaceutical Industries by 2.8% in the 3rd quarter. IFM Investors Pty Ltd now owns 183,771 shares of the company's stock valued at $1,874,000 after buying an additional 5,075 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Up 12.8 %

TEVA traded up $1.78 during trading on Wednesday, reaching $15.74. 38,496,364 shares of the company's stock were exchanged, compared to its average volume of 10,795,424. The company's fifty day moving average price is $13.70 and its 200-day moving average price is $11.72. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02. The firm has a market capitalization of $17.64 billion, a PE ratio of -33.48, a P/E/G ratio of 1.67 and a beta of 1.04. Teva Pharmaceutical Industries Limited has a fifty-two week low of $7.09 and a fifty-two week high of $16.13.

Insider Activity at Teva Pharmaceutical Industries

In related news, VP Eric Drape sold 173,261 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the transaction, the vice president now owns 1 shares of the company's stock, valued at approximately $13.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Mark Sabag sold 100,000 shares of the firm's stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the sale, the executive vice president now owns 382,590 shares of the company's stock, valued at $5,172,616.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Eric Drape sold 173,261 shares of the business's stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $13.05, for a total value of $2,261,056.05. Following the completion of the transaction, the vice president now owns 1 shares of the company's stock, valued at $13.05. The disclosure for this sale can be found here. Over the last quarter, insiders sold 358,972 shares of company stock worth $4,739,820. 0.55% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TEVA. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 target price on the stock in a research report on Friday, March 8th. Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and lifted their price objective for the company from $10.00 to $14.00 in a research report on Tuesday, January 23rd. Barclays increased their target price on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an "overweight" rating in a report on Monday, February 5th. Piper Sandler raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $12.00 to $19.00 in a report on Monday, February 12th. Finally, The Goldman Sachs Group increased their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a "neutral" rating in a report on Monday, February 5th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and an average target price of $13.78.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.